← 返回前沿论文

IFNγ通过抗原特异性 T 细胞增强逃逸变异肿瘤细胞的铁死亡,从而控制异质性肿瘤

英文原题:Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity.

查看英文原题

Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity.

PubMed 2026/09/02(内容时间) Cancer Immunol Res Q1 · IF 7.9(JCR 2025)

研究概要

这些发现表明,将铁死亡诱导剂与免疫治疗相结合,可能克服逃逸变异肿瘤克隆所带来的限制,为癌症治疗提供一种有前景的策略。

中文摘要

肿瘤团块常表现出异质性,包括缺乏抗原呈递机制和/或肿瘤抗原的逃逸变异克隆,这对免疫治疗构成了重大挑战。铁死亡是一种由铁依赖性脂质过氧化驱动的调节性细胞死亡形式,已被证明能有效诱导多种肿瘤细胞死亡。近期研究报道,IFNγ抑制system Xc-的表达,从而增强铁死亡的诱导。基于此,我们假设将免疫治疗与铁死亡诱导剂联合使用,可增强对抗原阳性及抗原阴性肿瘤细胞的抗肿瘤效果。我们发现,将铁死亡诱导剂RSL3与MART-1特异性T细胞受体工程化T细胞联合使用,可根除由人黑色素瘤细胞及其β2-微球蛋白敲除对应细胞组成的异质性肿瘤模型。在NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic小鼠中,该联合疗法对具有异质性的肿瘤表现出显著的抗肿瘤效果。这些发现表明,将铁死亡诱导剂与免疫治疗相结合,可克服逃逸变异肿瘤克隆所带来的局限,为癌症治疗提供了一种有前景的策略。

展开英文摘要原文

Tumor masses often exhibit heterogeneity, including escape variant clones that lack antigen-presenting machinery and/or tumor antigens, which poses a major challenge to immunotherapy. Ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, has been shown to effectively induce cell death in various tumor cells. Recent studies have reported that IFNγ suppresses the expression of system Xc-, thereby enhancing the induction of ferroptosis. Based on this, we hypothesized that combining immunotherapy with ferroptosis inducers could enhance antitumor effects against both antigen-positive and antigen-negative tumor cells. We found that combining RSL3, a ferroptosis inducer, with MART-1-specific T-cell receptor-engineered T cells eradicates a heterogeneous tumor model consisting of human melanoma cells and their β2-microglobulin knockout counterparts. In NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic mice, this combination therapy demonstrates a significant antitumor effect against tumors with heterogeneity. These findings suggest that integrating ferroptosis inducers with immunotherapy could overcome the limitations imposed by escape-variant tumor clones, offering a promising strategy for cancer treatment.

论文信息

作者
Ehara D、Yasui K、Yoneda M、Muraoka D、Deng S、Miao P、Jiang C、Sun H
单位
Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.Japan
期刊
Cancer immunology research2026 Sep 2
原文标识
PubMed 42397036 · DOI 10.1158/2326-6066.CIR-25-0175